Despite the fact that more than a third of U.S. adults are obese, it's been an uphill battle for developers of obesity treatments.» Read More
SHANGHAI, Aug 25- The entanglement of H.J. Heinz Co. in China's latest food scare highlights a key concern for international and local firms- how to keep track of ingredients from diverse sources in a country where food supply tracing technologies are far from the norm.
WASHINGTON, Aug 7- An influential U.S. senator is encouraging the Internal Revenue Service to stamp out deals that allow companies to relocate their headquarters overseas in search of lower tax rates.
*Expects key drug launches in fourth quarter despite FDA delay. Aug 7- Political opposition to tax-inversion deals will not stop Mylan Inc's purchase of some non-U.S. businesses from Abbott Laboratories, Chief Executive Heather Bresch said, even as some companies have backed away from such tax arrangements.
*Cuts top end of FY earnings forecast to $3.45/ shr from $3.60/ shr. Aug 7- Mylan Inc shaved the top end of its full-year revenue and earnings forecasts, citing delays in approval from the U.S. Food and Drug Administration for key generic drugs that it plans to launch this year.
SHANGHAI/ HONG KONG, July 29- With green-tea flavoured toothpaste and pickled plum juice, an army of Chinese retailers is tapping local tastes to whittle away market share from global rivals that are banking their future growth on the world's second-largest consumer market.
Surely Congress didn't mean to include a "poison pill" for the Affordable Care Act when it passed it, says law professor Tim Jost.
After a split ruling on Obamacare from the courts, who gets the last word? Law professor Dan Eaton weighs in.
LONDON/ MUMBAI, July 22- Indian generics firm Lupin, some U.S. drugmakers looking for a tax-saving deal in Europe and private equity funds are planning to bid for a range of older drugs being auctioned by GlaxoSmithKline, five sources familiar with the matter said.
Do US firms have a duty to sacrifice their own interests for the broader good of the country?, asks law professor Dan Eaton.
Some of Wednesday's midday movers:
*Sanofi mulls fate of 200 older drugs including Plavix. *Sanofi also held talks with TPG and Warburg Pincus. PARIS, July 16- Sanofi has held talks with Abbott Laboratories, Mylan and private equity firms over the possible sale of a 6.3 billion euro portfolio of mature drugs, according to an internal document seen by Reuters.
Sanofi talked with Abbott Laboratories, Mylan and private equity firms over selling a portfolio of mature drugs, according to a document.
PARIS, July 16- Sanofi has held talks with Abbott Laboratories, Mylan and private equity firms over the possible sale of a 6.3 billion euro portfolio of mature drugs, according to an internal document seen by Reuters.
Treasury Secretary Jack Lew has urged Congress to crack down on merger deals in which companies seek to relocate overseas to cut US taxes.
Stocks may respond more to earnings news than the Fed Wednesday, now that Fed Chair Janet Yellen's first day of testimony is out of the way.
Increasingly, drug makers and medical device companies have found a way to self-medicate when it comes to taxes and regulation.
*Citigroup to pay $7 bln to settle U.S. mortgage probe. NEW YORK, July 14- U.S. stocks ended higher on Monday, with the Dow Jones industrial average hitting an intraday record, lifted by Citigroup's better-than-expected earnings and more deals in the healthcare space. Citigroup Inc shares jumped 3 percent to $48.42 and gave the S&P 500 one of its biggest boosts.
Stocks climbed on Monday, with the S&P 500 bouncing back from weekly losses, after Citigroup's earnings beat estimates.
*Citigroup to pay $7 bln to settle U.S. mortgage probe. NEW YORK, July 14- U.S. stocks rose on Monday with the Dow Jones industrial average hitting a new intraday high, lifted by better than expected earnings from Citigroup and more deals in the healthcare space.
July 14- Generic drugmaker Mylan Inc said on Monday it would buy Abbott Laboratories' branded specialty and generics business in developed markets outside the United States in a $5.3 billion deal that will bolster its product line and also cut its tax bill.